Featured Companies

Compass Pathways Plc

NASDAQ: CMPS

Psychedelic Medicine · Clinical-Stage Biopharmaceuticals

The most advanced psychedelic-medicine company in the world — two successful Phase 3 trials, an active rolling NDA at the FDA, and a White House Executive Order accelerating the runway to commercial launch. Wall Street's mean target implies ~167% upside; the high target is a potential 7x.

• Two successful Phase 3 trials of COMP360 synthetic psilocybin in treatment-resistant depression.
• Rolling NDA filing at the FDA, with submission completion targeted for Q4 2026.
• April 2026 White House Executive Order directing the FDA to accelerate psychedelic approvals.
• Cash runway extends into 2028 — straight through commercial launch readiness.

View Full Profile